Literature DB >> 10843868

Gene transfer of dominant negative Rho kinase suppresses neointimal formation after balloon injury in pigs.

Y Eto1, H Shimokawa, J Hiroki, K Morishige, T Kandabashi, Y Matsumoto, M Amano, M Hoshijima, K Kaibuchi, A Takeshita.   

Abstract

Restenosis after angioplasty still remains a major problem for which neointimal formation appears to play an important role. Recent studies in vitro suggested that Rho kinase, a target protein of Rho, is important in various cellular functions. We thus examined whether Rho kinase is involved in the restenotic changes after balloon injury. In vivo gene transfer was performed immediately after balloon injury in both sides of the porcine femoral arteries with adenoviral vector encoding either a dominant negative form of Rho kinase (AdDNRhoK) or beta-galactosidase (AdLacZ) as a control. One week after the transfer, immunohistochemistry confirmed the successful gene expression in the vessel wall, whereas 2 wk after the transfer, Western blotting showed the functional upregulation of Rho kinase at the AdLacZ site and its suppression at the AdDNRhoK site. Angiography showed the development of a stenotic lesion at the AdLacZ site where histological neointimal formation was noted, whereas those changes were significantly suppressed at the AdDNRhoK site. These results indicate that Rho kinase is involved in the pathogenesis of neointimal formation after balloon injury in vivo.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10843868     DOI: 10.1152/ajpheart.2000.278.6.H1744

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  21 in total

Review 1.  Nonviral gene transfer strategies for the vasculature.

Authors:  Jennifer L Young; David A Dean
Journal:  Microcirculation       Date:  2002-01       Impact factor: 2.628

Review 2.  RhoA/Rho-kinase, vascular changes, and hypertension.

Authors:  K Chitaley; D Weber; R C Webb
Journal:  Curr Hypertens Rep       Date:  2001-04       Impact factor: 5.369

3.  Direct effects of Rho-kinase inhibitor on pial microvessels in rabbits.

Authors:  Masakazu Kotoda; Tadahiko Ishiyama; Noriyuki Shintani; Takashi Matsukawa
Journal:  J Anesth       Date:  2014-08-24       Impact factor: 2.078

4.  The cytoskeletal protein ezrin regulates EC proliferation and angiogenesis via TNF-alpha-induced transcriptional repression of cyclin A.

Authors:  Raj Kishore; Gangjian Qin; Corinne Luedemann; Evelyn Bord; Allison Hanley; Marcy Silver; Mary Gavin; Young-sup Yoon; David Goukassian; David Goukassain; Douglas W Losordo
Journal:  J Clin Invest       Date:  2005-06-16       Impact factor: 14.808

Review 5.  "Venopathy" at work: recasting neointimal hyperplasia in a new light.

Authors:  Alexander S Yevzlin; Micah R Chan; Yolanda T Becker; Prabir Roy-Chaudhury; Timmy Lee; Bryan N Becker
Journal:  Transl Res       Date:  2010-08-13       Impact factor: 7.012

Review 6.  Rho kinase (ROCK) inhibitors.

Authors:  James K Liao; Minoru Seto; Kensuke Noma
Journal:  J Cardiovasc Pharmacol       Date:  2007-07       Impact factor: 3.105

Review 7.  Therapeutic potential of RhoA/Rho kinase inhibitors in pulmonary hypertension.

Authors:  M Oka; K A Fagan; P L Jones; I F McMurtry
Journal:  Br J Pharmacol       Date:  2008-06-09       Impact factor: 8.739

Review 8.  Rho/Rho-associated coiled-coil forming kinase pathway as therapeutic targets for statins in atherosclerosis.

Authors:  Naoki Sawada; James K Liao
Journal:  Antioxid Redox Signal       Date:  2013-09-24       Impact factor: 8.401

Review 9.  Possible roles of 5-HT in vein graft failure due to intimal hyperplasia 5-HT, nitric oxide and vein graft.

Authors:  Akio Kodama; Takeo Itoh; Kimihiro Komori
Journal:  Surg Today       Date:  2013-03-28       Impact factor: 2.549

Review 10.  Transcription factor and kinase-mediated signaling in atherosclerosis and vascular injury.

Authors:  Neeta Adhikari; Nathan Charles; Ute Lehmann; Jennifer L Hall
Journal:  Curr Atheroscler Rep       Date:  2006-05       Impact factor: 5.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.